Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis.

Zhang, Yue; Fang, Yisheng; Wu, Jianhua; Huang, Genjie; Bin, Jianping; Liao, Yulin; Shi, Min; Liao, Wangjun; Huang, Na

Zhang, Yue; Fang, Yisheng; Wu, Jianhua; Huang, Genjie; Bin, Jianping; Liao, Yulin; Shi, Min; Liao, Wangjun; Huang, Na.

Afiliação

Zhang Y; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Fang Y; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wu J; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Huang G; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Bin J; Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Liao Y; Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Shi M; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Liao W; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Huang N; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Front Pharmacol ; 13: 817662, 2022.

Article em En | MEDLINE | ID: mdl-35431928

Palavras-chave

CTLA-4; FAERS; PD-1/PD-L1; combination therapy; diabetes mellitus; immune checkpoint inhibitors; pancreatic adverse events; pancreatitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google